SPY417.26+1.39 0.33%
DIA341.86+1.53 0.45%
IXIC14,052.34+13.58 0.10%

BRIEF-Algernon Pharmaceuticals Submits U.S. FDA Pre-Ind Meeting Request For Psychedelic Drug Dmt Clinical Research Program For Stroke

· 03/17/2021 07:45
BRIEF-Algernon Pharmaceuticals Submits U.S. FDA Pre-Ind Meeting Request For Psychedelic Drug Dmt Clinical Research Program For Stroke

- Algernon Pharmaceuticals Inc AGN.CD:

  • ALGERNON PHARMACEUTICALS INC - SUBMITS U.S. FDA PRE-IND MEETING REQUEST FOR PSYCHEDELIC DRUG DMT CLINICAL RESEARCH PROGRAM FOR STROKE

Source text for Eikon: ID:nGNX2GK2XB

Further company coverage: AGN.CD


((Reuters.Briefs@thomsonreuters.com;))